Last updated: June 1, 2026
Xerava (eravacycline) Suppliers: Who Makes the Drug Product, API, and Key Components?
Xerava (eravacycline) supply is tied to a narrow set of contract manufacturing and specialty chemical supply chains supporting Pfizer’s eravacycline commercialization under NDA/labeling controls. The commercially relevant “supplier” landscape is best read through: (1) the labeled drug product manufacturer(s) on the FDA label and (2) any listed API or intermediate suppliers in registration dossiers, quality agreements, and manufacturing listings tied to the NDA holder’s CMC program.
Who are the labeled manufacturers and suppliers for Xerava (eravacycline) in the FDA label?
Answer (label-controlled sourcing): Xerava’s “supplier” set for procurement and regulatory submissions is anchored to the manufacturer listed on the prescribing information (drug product) and the NDA holder’s CMC/quality system that controls release and distribution. These entries determine the parties that can typically be named in quality agreements and regulatory documentation for drug product supply continuity.
What does the Xerava label typically list as the drug product manufacturer?
- Drug product manufacturer (site(s) responsible for final drug product manufacture and release)
- NDA holder/distributor (commercial responsibility and regulatory sponsor for supply continuity)
- Packaging/manufacturing operations (where applicable)
What procurement and IP diligence must track for Xerava supply?
- GMP site identity tied to NDA labeling
- Batch release responsibilities and QA disposition points
- Change-control history for manufacturing site shifts and process modifications
- Cold-chain or storage conditions handling at finished goods level
Which companies supply the eravacycline API for Xerava?
Answer (API sourcing): For Xerava, API sourcing is controlled via Pfizer’s eravacycline CMC network, with API or key intermediates supplied under GMP and quality agreements linked to the NDA’s approved manufacturing and control strategy. In practical terms, API “suppliers” used in procurement are the facilities that are either:
- listed in the application/CMC package as qualified API manufacturing sites, or
- contract-manufactured under Pfizer’s approved change controls and listed in quality docs for incoming material release.
What suppliers matter for CMC risk on eravacycline API?
- Intermediate purity controls affecting:
- impurity profile and specification fit
- batch-to-batch consistency for stability and sterility batches
- Tight control of:
- polymorph/solid-state behavior where relevant
- residual solvents and catalytic residues
- Sourcing continuity risk:
- single-source intermediates
- catalyst and specialized reagent availability
What contract manufacturers make Xerava (eravacycline) drug product formulation and sterile fill-finish?
Answer (drug product manufacturing): Xerava’s production requires a sterile injectable manufacturing stack: drug substance to drug product conversion plus sterile filtration, aseptic processing (as applicable), filling, and packaging. The practical “supplier” set for operations is the GMP sterile fill-finish and aseptic manufacture sites that appear in FDA labeling and/or CMC documentation.
What site functions typically sit inside Xerava supply chains?
- Drug product manufacturing (bulk drug product)
- Sterile fill-finish (vial preparation, filling, stoppering, sealing)
- Labeling and packaging under approved artwork and configuration controls
- Secondary packaging and distribution warehousing setup
How does NDA-controlled CMC limit “supplier switching” for Xerava?
Answer: Xerava supply cannot be freely switched between manufacturers without CMC comparability and regulatory reporting under FDA postapproval manufacturing change pathways. The sponsor’s quality system and the NDA’s approved manufacturing sites constrain which suppliers can be used without triggering:
- prior approval supplements (PAS) for material changes
- comparability protocols and bridging studies
- postapproval reporting obligations
What triggers re-approval risk when switching Xerava suppliers?
- Sterile manufacturing process changes
- Fill-finish line changes impacting container closure integrity
- API source changes that alter impurity profile
- Analytical method changes needed to revalidate specifications
What is the Orange Book status of Xerava and how does that affect suppliers?
Answer: Xerava’s regulatory exclusivity and patent estate affect generic and biosimilar entry, which in turn affects supplier diversity. If there is limited generic competition, the number of validated commercial suppliers stays small, concentrating supply in the NDA holder’s established CMC network.
What supplier landscape shift occurs after generic entry?
- Multiple ANDA manufacturers sourcing API and producing sterile injectables
- New contract manufacturing sites qualified for product-specific comparability
- Potential price pressure and longer-term supply diversification
Which companies are likely involved in Xerava manufacturing under Pfizer’s quality system?
Answer: For Xerava, the supplier universe is typically:
- the NDA holder (commercial sponsor and quality system owner)
- qualified drug product manufacturing sites listed in labeling/CMC
- qualified API manufacturing sites and/or intermediate suppliers under approved change control
How to treat “suppliers” for Xerava in diligence
- Treat as supplier candidates only those:
- named in FDA label/manufacturing section
- referenced in approved CMC as qualified sites
- capable of sterile injectable compliant operations for drug product
Key Takeaways
- Xerava supplier identification in practice is governed by FDA label-listed drug product manufacturer(s) and Pfizer’s NDA-controlled CMC network.
- API suppliers are constrained to qualified GMP sites approved in the eravacycline CMC package and quality agreements.
- Sterile fill-finish and aseptic manufacturing sites are the operational “supplier nodes” that matter most for availability risk.
- Patent and exclusivity status influences supplier diversity by shaping generic entry timing and downstream manufacturing competition.
FAQs
-
Does Xerava have multiple FDA-labeled drug product manufacturing sites?
Supplier count depends on which GMP sites are named in the FDA label manufacturing section.
-
Can an alternative eravacycline API source supply Xerava under Pfizer?
Only if Pfizer’s CMC change controls and FDA comparability requirements support the change without specification drift.
-
What parts of Xerava supply chain are highest risk for shortages?
Qualified sterile fill-finish lines and key eravacycline intermediate or API manufacturing steps.
-
How does potential generic entry change Xerava supplier options?
ANDA approvals typically add competing sterile injectable producers, expanding validated supply.
-
Are labeling changes ever used to add new Xerava manufacturing sites?
Manufacturing site additions generally require FDA postapproval submissions and comparability work under the NDA holder’s quality system.
References
No sources are provided in this prompt.
